

medac
Hämatologie


NOVARTIS
ONCOLOGY

sobi

CSL Behring
Biotherapies for Life™

octapharma

Thank you
to our sponsors!



Medac 400 €
Octapharma 500 €
CSL Behring 300 €
Novartis 250€
Sobi 500 €

Requests / Info:
carl-friedrich.classen@med.uni-rostock.de
Tel. 0381 / 494 7255
Fax. 0381 / 494 686 7255

ZOOM login-data:
Fri.11.Feb.2022. 9:00

<https://uni-rostock-de.zoom.us/j/64996804167?pwd=OFNxUmtJUHVRQWM2NjFqbK9EUFJhdz09>

Meeting-ID: 649 9680 4167
Kenncode: 082485

Sat.12.Feb.2022. 9:00

<https://uni-rostock-de.zoom.us/j/69104973308?pwd=RXIEUitWZ1c0akRGSVVWV2YxMXZjdz09>

Meeting-ID: 691 0497 3308
Kenncode: 870310

Come Together Evening Fri.11.Feb.2022.

<https://uni-rostock-de.zoom.us/j/63376506990?pwd=djd4Qm56a05tS2dKd3JjU1daYTIJdz09>

Meeting-ID: 633 7650 6990
Kenncode: 124450

carl-friedrich.classen@med.uni-rostock.de
Tel. 0381 / 494 7255
Fax. 0381 / 494 686 7255
Mobil 0160 9151 4989

Kinder- und Jugendklinik der
Universitätsmedizin Rostock
Stellv. Direktorin Prof. Dr. A. Bertsche
Ernst-Heydemann-Str. 8
D - 18057 Rostock
AG Hirntumorforschung
Prof. Dr. med. Carl Friedrich Classen

Universität
Rostock Traditio et Innovatio

Universitätsmedizin
Rostock

Kinder- und Jugendklinik
Universitätsmedizin Rostock



Pre-Programme

16th ROSTOCK SYMPOSION
for Tumor Immunology and Brain
Tumor Research in Pediatrics
Friday 11 and Sat. 12 Feb. 2022
Virtual Congress
– login data see below

Preliminary programme

(maybe subject to changes)

Friday 11.2.2022.

Immune System against Staphylococcus aureus
Barbara Bröker, Greifswald

I will survive, but... Osteonecrosis in adolescents
Michaela Kuhlen, Augsburg

FGF10 triggers de novo alveologenesis in a BPD
model: impact on the resident mesenchymal
niche cells
Cho-Ming Chao, Rostock

Therapeutic anticoagulation impacts MR
morphologic recurrence patterns in glioblastoma
– a matched-pair analysis.
Daniel Dubinski, Rostock

Break

Targeting intratumoral Tregs for cancer
immunotherapy
Tobias Wertheimer, Regensburg

CDK inhibitors affect neuroblastoma growth and
induce immunogenic cell death
Pia Bordihn, Rostock

Elucidating the role of connexin in cellular
networks of glioblastoma
Hannah Strobel, Ulm

Lunch break - Friday afternoon

Cytokine Profiles in the Cerebrospinal Fluid
of Glioma Patients
Markus Kowarik, Tübingen

CDK4/6 blockade is as effective as immune-
checkpoint-inhibition in tumor growth control
of Mlh1^{-/-} and Msh2loxP/loxP ;TgTg(Vil1-cre)
mice
Claudia Maletzki, Rostock

The genomic and transcriptional landscape
of PCNSL
Josefine Radke, Greifswald

EBV and Covid-19
Kunal Garg, Ulm

Break

Ways to Dissect Inflammatory and
Autoimmune Phenotypes in Psychiatric
Disorders (AF and SZ)
Christian Scheiber, Ulm

Treatment with ONC201/TIC10 along with
Bcl-xL/Bcl-2 inhibition has a synergistic anti-
neoplastic activity against medulloblastoma
cells in vitro
Antonia Spilz, Georg Karpel-Massler, Ulm

Reelin: A new potential microenvironmental
factor contributing to Glioblastoma invasion
Amina Hadzalic, Ulm

COME TOGETHER !!

20:00 Live Concert with Anette Wizisla

Saturday 12.2.2022.

The Bcl-2 family in brain tumours
Mike Andrew Westhoff, Ulm

The Bcl-2-family in Glioblastoma
Therapy
Anne Fleischmann, Ulm

Hemeadsorption and functional
properties of exosomes sprechen
Marion Schneider, Ulm

Final results of the Choroid Plexus
Tumor study CPT-SIOP-2000
Uwe Kordes, Hamburg

Break

Synergy between TMZ and
individualized multimodal
immunotherapy to improve Overall
Survival of IDH1 wild-type MGMT
promoter-unmethylated GBM patients
Stefaan van Gool, Köln

Evaluation of myelo-monocytic
differentiation of congenital neutropenia
patient derived induced pluripotent stem
cells
Dorothea Stalman, Rostock

Development of a FACS based method
for isolation of neurovascular unit cells
and its application to neurological
disease
Tim Pütz, Rostock